Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Patent metadata

Field	Value
Publication number	US-12070491-B2
Application number	US-202117502170-A
Country	US
Kind code	B2
Filing date	Oct 15, 2021
Priority date	Dec 23, 2014
Publication date	Aug 27, 2024
Grant date	Aug 27, 2024

Abstract

A peptide consists of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8+ T cells. A composition contains a peptide consisting of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214), an adjuvant, and a pharmaceutically acceptable carrier.

First claim

The invention claimed is:

1. A peptide consisting of the amino acid sequence IYVTSIEQI (SEQ ID NO: 214) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1 , wherein said peptide has the ability to bind to a major histocompatibility complex (MHC) class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8+ T cells.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

4. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

5. The peptide in the form of a pharmaceutically acceptable salt of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

6. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

7. The composition of claim 6 , wherein the peptide is in the form of a chloride salt.

8. The composition of claim 6 , wherein the peptide is in the form of an acetate salt.

9. The composition of claim 6 , further comprising an adjuvant selected from the group consisting of imiquimod, resiquimod, granulocyte-macrophage colony-stimulating factor (GM-CSF), cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides, polyinosinic:polycytidylic acid (poly-(I:C)), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

10. The composition of claim 9 , wherein the adjuvant is IL-2.

11. The composition of claim 9 , wherein the adjuvant is IL-7.

12. The composition of claim 9 , wherein the adjuvant is IL-12.

13. The composition of claim 9 , wherein the adjuvant is IL-15.

14. The composition of claim 9 , wherein the adjuvant is IL-21.

15. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises a buffer.

16. A pegylated peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214) or a pharmaceutically acceptable salt thereof, wherein a polyethylene glycol (PEG) is cross-linked to the amino acid sequence.

17. The peptide of claim 16 , wherein the pharmaceutically acceptable salt is chloride salt.

18. The peptide of claim 16 , wherein the pharmaceutically acceptable salt is acetate salt.

19. A composition comprising the pegylated peptide of claim 16 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Weinschenk Toni
• Mahr Andrea
• Fritsche Jens
• Mueller Phillip
• Wiebe Anita
• Kutscher Sarah

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title

• A61K2039/5154

  Antigen presenting cells [APCs], e.g. dendritic cells or macrophages · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title